World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

Miia Kivipelto, Francesca Mangialasche, Heather M Snyder, Ricardo Allegri, Sandrine Andrieu, Hidenori Arai, Laura Baker, Sylvie Belleville, Henry Brodaty, Sonia M Brucki, Ismael Calandri, Paulo Caramelli, Christopher Chen, Howard Chertkow, Effie Chew, Seong H Choi, Neerja Chowdhary, Lucía Crivelli, Rafael De La Torre, Yifeng Du, Tarun Dua, Mark Espeland, Howard H Feldman, Maris Hartmanis, Tobias Hartmann, Megan Heffernan, Christiani J Henry, Chang H Hong, Krister Håkansson, Takeshi Iwatsubo, Jee H Jeong, Gustavo Jimenez-Maggiora, Edward H Koo, Lenore J Launer, Jenni Lehtisalo, Francisco Lopera, Pablo Martínez-Lage, Ralph Martins, Lefkos Middleton, José L Molinuevo, Manuel Montero-Odasso, So Y Moon, Kristal Morales-Pérez, Ricardo Nitrini, Haakon B Nygaard, Yoo K Park, Markku Peltonen, Chengxuan Qiu, Yakeel T Quiroz, Rema Raman, Naren Rao, Vijayalakshmi Ravindranath, Anna Rosenberg, Takashi Sakurai, Rosa M Salinas, Philip Scheltens, Gustavo Sevlever, Hilkka Soininen, Ana L Sosa, Claudia K Suemoto, Mikel Tainta-Cuezva, Lina Velilla, Yongxiang Wang, Rachel Whitmer, Xin Xu, Lisa J Bain, Alina Solomon, Tiia Ngandu, Maria C Carrillo, Miia Kivipelto, Francesca Mangialasche, Heather M Snyder, Ricardo Allegri, Sandrine Andrieu, Hidenori Arai, Laura Baker, Sylvie Belleville, Henry Brodaty, Sonia M Brucki, Ismael Calandri, Paulo Caramelli, Christopher Chen, Howard Chertkow, Effie Chew, Seong H Choi, Neerja Chowdhary, Lucía Crivelli, Rafael De La Torre, Yifeng Du, Tarun Dua, Mark Espeland, Howard H Feldman, Maris Hartmanis, Tobias Hartmann, Megan Heffernan, Christiani J Henry, Chang H Hong, Krister Håkansson, Takeshi Iwatsubo, Jee H Jeong, Gustavo Jimenez-Maggiora, Edward H Koo, Lenore J Launer, Jenni Lehtisalo, Francisco Lopera, Pablo Martínez-Lage, Ralph Martins, Lefkos Middleton, José L Molinuevo, Manuel Montero-Odasso, So Y Moon, Kristal Morales-Pérez, Ricardo Nitrini, Haakon B Nygaard, Yoo K Park, Markku Peltonen, Chengxuan Qiu, Yakeel T Quiroz, Rema Raman, Naren Rao, Vijayalakshmi Ravindranath, Anna Rosenberg, Takashi Sakurai, Rosa M Salinas, Philip Scheltens, Gustavo Sevlever, Hilkka Soininen, Ana L Sosa, Claudia K Suemoto, Mikel Tainta-Cuezva, Lina Velilla, Yongxiang Wang, Rachel Whitmer, Xin Xu, Lisa J Bain, Alina Solomon, Tiia Ngandu, Maria C Carrillo

Abstract

Reducing the risk of dementia can halt the worldwide increase of affected people. The multifactorial and heterogeneous nature of late-onset dementia, including Alzheimer's disease (AD), indicates a potential impact of multidomain lifestyle interventions on risk reduction. The positive results of the landmark multidomain Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) support such an approach. The World-Wide FINGERS (WW-FINGERS), launched in 2017 and including over 25 countries, is the first global network of multidomain lifestyle intervention trials for dementia risk reduction and prevention. WW-FINGERS aims to adapt, test, and optimize the FINGER model to reduce risk across the spectrum of cognitive decline-from at-risk asymptomatic states to early symptomatic stages-in different geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and adapt multidomain interventions across various countries and settings, to facilitate data sharing and analysis across studies, and to promote international joint initiatives to identify globally implementable and effective preventive strategies.

Keywords: Alzheimer's disease; World-Wide FINGERS; cognitive impairment; dementia; lifestyle; multidomain intervention; prevention; randomized controlled trial.

Conflict of interest statement

CONFLICTS OF INTEREST

Maria C. Carrillo and Heather M. Snyder are full-time employees of the Alzheimer’s Association. Henry Brodaty (MYB) is on the Advisory Board for Nutricia Australia. Rafael De la Torre and José L. Molinuevo are full-time employees of the Hospital del Mar Medical Research Institute and the Barcelonabeta Brain Research Institute, respectively. All the other co-authors declare no conflicts of interest in connection with this work.

© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.

Figures

FIGURE 1
FIGURE 1
World map with countries that are involved in the World-Wide FINGERS Network. Dark blue indicates involvement in ongoing World-Wide FINGERS studies. Studies are currently planned in countries marked with light blue
FIGURE 2
FIGURE 2
Levels defined for the trials participating in the World-Wide FINGERS Network

References

    1. ADI. Alzheimer’s Disease International. World Alzheimer Report 2018: the state of the art of dementia research: new frontiers. 2018.
    1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337–1342.
    1. Langa KM, Larson EB, Crimmins EM, et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017;177:51–58.
    1. Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N EnglJ Med. 2016;374:523–532.
    1. Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80:1888–1894.
    1. Ding M, Qiu C, Rizzuto D, Grande G, Fratiglioni L. Tracing temporal trends in dementia incidence over 25 years in central Stockholm, Sweden. Alzheimers Dement. 2020;16:770–778.
    1. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382:1405–1412.
    1. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78:1456–1463.
    1. Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet. 2013;381:2016–2023.
    1. Gao S, Ogunniyi A, Hall KS, et al. Dementia incidence declined in African-Americans but not in Yoruba. Alzheimers Dement. 2016;12:244–251.
    1. Ohara T, Hata J, Yoshida D, et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology. 2017;88:1925–1932.
    1. Wu YT, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time—current evidence. Nat Rev Neurol. 2017;13:327–339.
    1. Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N EnglJ Med. 2013;369:2275–2277.
    1. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–794.
    1. Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14:653–666.
    1. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–2263.
    1. Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013;9:657–665.
    1. Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimers Dement. 2018;14:263–270.
    1. Solomon A, Turunen H, Ngandu T, et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 2018;75:462–470.
    1. Marengoni A, Rizzuto D, Fratiglioni L, et al. The effect of a 2-year intervention consisting of diet, physical exercise, cognitive training, and monitoring of vascular risk on chronic morbidity-the FINGER randomized controlled trial. J Am Med Dir Assoc. 2018;19:355–360.e1.
    1. Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377–389.
    1. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388:797–805.
    1. Chhetri JK, de Souto Barreto P, Cantet C, et al. Effects of a 3-year multi-domain intervention with or without Omega-3 supplementation on cognitive functions in older subjects with increased CAIDE dementia scores. J Alzheimers Dis. 2018;64:71–78.
    1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673–2734.
    1. National Academies of Sciences, Engineering, and Medicine. Leshner, Alan I, Landis, Story, Stroud, Clare & Downey, Autumn, Preventing Cognitive Decline and Dementia: A Way Forward. Washington, DC: National Academies Press; 2017.10.17226/24782.
    1. WHO. Risk Reduction of Cognitive Decline and Dementia: World Health Organization Guidelines. Geneva: World Health Organization; 2019..
    1. Kivipelto M, Mangialasche F, Ngandu T, World Wide Fingers N. World Wide Fingers will advance dementia prevention. Lancet Neurol. 2018;17:27.
    1. Heffernan M, Andrews G, Fiatarone Singh MA, et al. Maintain your brain: protocol of a 3-year randomized controlled trial of a personalized multi-modal digital health intervention to prevent cognitive decline among community dwelling 55 to 77 year olds. J Alzheimers Dis. 2019;70:S221–S237.
    1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746.
    1. Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:965–975.
    1. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735–741.
    1. Carnero-Pardo C, Espejo-Martinez B, Lopez-Alcalde S, et al. Diagnostic accuracy, effectiveness and cost for cognitive impairment and dementia screening of three short cognitive tests applicable to illiterates. PLoS One. 2011;6:e27069.
    1. Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65:559–564.
    1. Rami L, Molinuevo JL, Sanchez-Valle R, Bosch B, Villar A. Screening for amnestic mild cognitive impairment and early Alzheimer’s disease with M@T (Memory Alteration Test) in the primary care population. Int J Geriatr Psychiatry. 2007;22:294–304.
    1. Barbera M, Mangialasche F, Jongstra S, et al. Designing an internet-based multidomain intervention for the prevention of cardiovascular disease and cognitive impairment in older adults: the HATICE trial. J Alzheimers Dis. 2018;62:649–663.
    1. Richard E, Moll van Charante EP, Hoevenaar-Blom MP, et al. Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. Lancet Digital Health. 2019;1:PE424-E34.
    1. Zulke A, Luck T, Pabst A, et al. —study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients. BMC Geriatr. 2019;19:203.
    1. Weninger S, Carrillo MC, Dunn B, et al. Collaboration for Alzheimer’s Prevention: principles to guide data and sample sharing in preclinical Alzheimer’s disease trials. Alzheimers Dement. 2016;12:631–632.
    1. Ohmann C, Banzi R, Canham S, et al. Sharing and reuse of individual participant data from clinical trials: principles and recommendations. BMJ Open. 2017;7:e018647.
    1. Institute of Medicine (IOM). Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: The National Academies Press; 2015. 10.17226/18998.
    1. EU. Data protection in the EU. The General Data Protection Regulation (GDPR). 2018. Available at: Accessed 10 March 2020.
    1. Ursin G, Stenbeck M, Chang-Claude J, et al.. Data must be shared-also with researchers outside of Europe. Lancet. 2019;394:1902–1903.
    1. Wolfson M, Wallace SE, Masca N, et al. DataSHIELD: resolving a conflict in contemporary bioscience—performing a pooled analysis of individual-level data without sharing the data. Int J Epidemiol. 2010;39:1372–1382.
    1. WHO. World Health Organization. Global Dementia Observatory (GDO). last accessed 10 March 2020.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa